Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00199823
Status:
COMPLETED
Last Update Posted:
2011-07-06
First Post:
2005-09-13
Brief Title:
Autologous Stem Cell Transplantation in Acute Myocardial Infarction
Sponsor:
Oslo University Hospital
Organization:
Oslo University Hospital
Study Overview
Official Title:
Autologous Stem Cell Transplantation in Acute Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objectives
Intracoronary transplantation of different cell populations have been used in acute myocardial infarction AMI with promising results The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells mBMC improve left ventricular ejection fraction LVEF after anterior wall AMI
Design
The ASTAMI study is a randomized controlled prospective study One hundred patients with acute anterior wall ST-elevation myocardial infarction STEMI treated with acute PCI are randomized in a 11 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control Left ventricular function exercise capacity biochemical status functional class quality of life and complications are validated at baseline and during a 12-month follow up
Intracoronary transplantation of different cell populations have been used in acute myocardial infarction AMI with promising results The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells mBMC improve left ventricular ejection fraction LVEF after anterior wall AMI
Design
The ASTAMI study is a randomized controlled prospective study One hundred patients with acute anterior wall ST-elevation myocardial infarction STEMI treated with acute PCI are randomized in a 11 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control Left ventricular function exercise capacity biochemical status functional class quality of life and complications are validated at baseline and during a 12-month follow up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None